Valneva

Valneva Debt/EBITDA

The Total Debt to EBITDA Ratio of Valneva (VLA.PA) as of Nov 3, 2026 is -2.23. In the previous year, Total Debt to EBITDA Ratio was 10.43 — a change of -121.36% (lower).

Debt/EBITDA

-2.23

YoY

-121.36%

Last updated:

Total Debt to EBITDA Ratio of Valneva is 2025 -2.23 . Total Debt to EBITDA Ratio of Valneva was 2024 10.43 . It decreases by -121.36% lower compared to the previous year.

The Valneva Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
5.44 EUR
Jan 1, 2019
14.28 EUR
Jan 1, 2020
-2.12 EUR
Jan 1, 2021
-2.40 EUR
Jan 1, 2022
-1.26 EUR
Jan 1, 2023
-2.89 EUR
Jan 1, 2024
10.43 EUR
Jan 1, 2025
-2.23 EUR
The Valneva Debt/EBITDA history
YEARDebt/EBITDAYoY
-2.23-121.36%
10.43-460.86%
-2.89+129.84%
-1.26-47.48%
-2.40+13.08%
-2.12-114.83%
14.28+162.62%
5.44-37.72%
8.73-115.82%
-55.19+583.30%
-8.08+26.90%
-6.36—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valneva Stock analysis

What does Valneva do? Valneva SE is a biopharmaceutical company specializing in the development, production, and marketing of vaccines for humans and animals. The company was founded in 2013 through the merger of French biotech company Vivalis and Austrian biotech company Intercell. Valneva focuses on developing vaccines for infectious diseases with a significant global burden but limited commercial demand. They work closely with governments and international organizations to improve access to their vaccines in developing countries. Valneva also has a strong presence in the animal vaccine market, producing vaccines for diseases in livestock and pets. They have developed and marketed several vaccines, including Ixiaro for Japanese encephalitis and VLA15, a vaccine candidate for Lyme disease. Overall, Valneva is an international company with an impressive pipeline of vaccine candidates and a commitment to addressing global health needs. Valneva is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valneva stock

Total Debt to EBITDA Ratio of Valneva is -2.23 in 2025.

Total Debt to EBITDA Ratio of Valneva changed from 10.43 to -2.23, representing a -121.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Valneva since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Valneva with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Valneva

All Key Metrics — Valneva